PTGDR2
Prostaglandin D2 receptor 2
As of the edition of 20 October 2026, PTGDR2 (prostaglandin D2 receptor 2, UniProt Q9Y5Y4) has 14 drugs tested at it and 12 companies on the list, 12 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y5Y4
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Lungs and airways; Immune system; Ear, nose and throat; Blood and lymph; Skin and connective tissue; Infections; Inherited and neonatal; Cancer
- Registered trials of its drugs
- 73
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 11 |
| Stopped | 3 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fevipiprant | Stopped | Phase 3 | none listed |
| AZD1981 | Went quiet | Phase 2 | none listed |
| Timapiprant | Went quiet | Phase 2 | none listed |
| BI-671800 | Went quiet | Phase 2 | none listed |
| MK-1029 | Went quiet | Phase 2 | none listed |
| Setipiprant | Went quiet | Phase 2 | none listed |
| QAV680 | Stopped | Phase 2 | none listed |
| ADC3680 | Went quiet | Phase 2 | none listed |
| BI 1021958 | Went quiet | Phase 1 | none listed |
| Vidupiprant | Went quiet | Phase 2 | none listed |
| ARRY-502 | Went quiet | Phase 2 | none listed |
| Ramatroban | Stopped | Phase 3 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 12 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Merck & Co. | Route A |
| AbbVie | Route A |
The other 9 companies at PTGDR2
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at PTGDR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.